| Primary | Period 1: Absolute Bioavailability Based on Ratio of Dose Normalized Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞ ) for TAK-906 | Bioavailability is defined as the proportion of a drug which enters the circulation when introduced into the body and so is able to have an active effect. Percent absolute bioavailability for plasma TAK-906, calculated as geometric least squares mean ratio: [Actual Dose (IV) x AUC∞ (oral)] / [Actual Dose (oral) x AUC∞ (IV)] multiplied (x) 100, where AUC∞ for IV infusion was normalized to a 50 mg dose. | Pharmacokinetic (PK) Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules followed by [14C]-TAK-906 100 μg [approximately 1 μCi], IV infusion in Period 1 were evaluated for this outcome measure. | Posted | | Geometric Least Squares Mean | 90% Confidence Interval | percent absolute bioavailability | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-906 50 mg + [14C]-TAK-906 100 μg | TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 μg [approximately 1 μCi], IV infusion, once on Day 1 of Treatment Period 1. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Period 2: Cum%Dose (UR): Cumulative Percentage of Total Radioactivity Excreted in Urine for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | percentage of dose | | Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Cum%Dose (FE): Cumulative Percentage of Total Radioactivity Excreted in Feces for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | percentage of dose | | Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Combined Cum%Dose: Cumulative Combined Percent of Total Radioactivity Excreted in Urine and Feces for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | percentage of dose | | Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 1: Cmax: Maximum Observed Plasma Concentration for TAK-906 and Metabolite (M23) After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng/mL | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-906 50 mg | TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Median | Full Range | hour (hr) | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-906 50 mg | TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-906 50 mg | TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the specified category. | Posted | | Geometric Mean | Geometric Coefficient of Variation | percentage of AUC | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-906 50 mg | TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: t(1/2)z : Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the specified category. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hours (hr) | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-906 50 mg | TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Liters | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-906 50 mg | TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | L/hr | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-906 50 mg | TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: Ceoi: Plasma Total Radioactivity Concentration at the End of Infusion for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | nanogramequivalents/milliliter(ng eq/mL) | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 100 μg | [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days. |
| |
| Secondary | Period 1: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/mL | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 100 μg | [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days. |
| |
| Secondary | Period 1: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/mL | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 100 μg | [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days. |
| |
| Secondary | Period 1: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hr | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 100 μg | [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days. |
| |
| Secondary | Period 1: Ceoi: Plasma Concentration at the End of Infusion for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | picograms (pg)/mL | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 100 μg | [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days. |
| |
| Secondary | Period 1: CL: Total Clearance for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | L/hr | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 100 μg | [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days. |
| |
| Secondary | Period 1: Vss: Volume of Distribution During the Terminal Disposition Phase for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Liters | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 100 μg | [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days. |
| |
| Secondary | Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | pg*hr/mL | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 100 μg | [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days. |
| |
| Secondary | Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | percentage of AUC | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 100 μg | [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days. |
| |
| Secondary | Period 1: t(1/2)z: Terminal Disposition Phase Half-life for [14C]-TAK-906 | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hr | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 100 μg | [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days. |
| |
| Secondary | Period 2: Cmax: Maximum Observed Plasma Concentration for TAK-906 and M23 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng/mL | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Median | Full Range | hr | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906 and M23 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category. | Posted | | Geometric Mean | Geometric Coefficient of Variation | percentage of AUC | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: t(1/2)z: Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hr | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Liters | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | L/hr | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: Cmax: Maximum Observed Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq/mL | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: Tmax: Time to Reach the Maximum Plasma Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Median | Full Range | hr | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: AUCt: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Time of the Last Common Time Point t for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/mL | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/mL | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/mL | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hr | | Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: Cmax: Maximum Observed Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq/mL | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: Tmax: Time to Reach the Maximum Whole Blood Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Median | Full Range | hr | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: AUClast: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/mL | | Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: AUC∞: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/mL | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration | | PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hr | | Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]-TAK-906 50 mg | [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2. |
| |